Publication Topic

Tao C, Nicholson G, Desai N, Sacks N, Sherwood R, Pokorney S. Budget impact of etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States. Abstract I9, AMCP Annual Meeting. J Manag Care Spec Pharm 31(3-a Suppl):S73; doi: 10.18553/jmcp.2025.31.3-a.s1. Houston, TX, March 21-April 3, 2025.

Nordyke RJ, Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051. PMID: 4012322.

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.

Haselkorn T, Hughes W, Schara-Schmidt U, Lennox A, Roca A, Miller B, Jensen I, Solomon F, et al. 2024. Abstract PCR257: Real-world impact of x-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Value in Health 27(12-Sup):S557; doi: 10.1016/j.val.2024.10.3499.

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024. Value in Health 27(12 Sup):S191; doi: 10.1016/j.jval.2024.10.973. Barcelona, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The cost-effectiveness of atidarsagene autotemcel (ARSACEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain. ISPOR Europe 2024, November 2024.

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, Valencia, Spain, 19–23 November 2024.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain. ISPOR Europe 2024, Barcelona, November 2024.

Suh M, Movva N, Pastula S, Izikson R, Rizzo C, La Via W, Machado M, Shin T, Bertizzolo L. 2024. Systematic literature review of RSV in young infants and children: Healthcare utilization and economics. PROSPERO 2024:CRD42024599256. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024599256.